Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Blinatumomab - Amgen

Drug Profile

Blinatumomab - Amgen

Alternative Names: AMG-103; Blincyto; MEDI-538; MT-103

Latest Information Update: 24 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Micromet Inc
  • Developer Amgen; Astellas Pharma; M. D. Anderson Cancer Center; Merck & Co; Micromet Inc; National Cancer Institute (USA); University of California, Davis
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - B-cell prolymphocytic leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; B-cell lymphoma; Mantle-cell lymphoma; T-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Hairy cell leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Phase II/III Non-Hodgkin's lymphoma
  • Phase II Diffuse large B cell lymphoma
  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 22 Jan 2019 The European Commission approves blinatumomab in Philadelphia chromosome negative (Ph-) CD19 positive B-cell precursor acute lymphoblastic leukemia (In adults) with first or second complete remission with minimal residual disease
  • 01 Dec 2018 Efficacy and adverse events data from the phase II portion of the phase II/III trial in Non-Hodgkin lymphoma presented at the 60th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2018)
  • 01 Dec 2018 Efficacy and adverse events data from an expanded access study in Precursor B-cell lymphoblastic leukaemia-lymphoma presented at the 60th Annual Meeting and Exposition of the American Society of Haematology (ASH-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top